{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:18:20Z","timestamp":1792732700122,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jhep.2023.06.013","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T22:47:23Z","timestamp":1689806843000},"page":"1150-1158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2084-8810","authenticated-orcid":false,"given":"David J.","family":"Kuter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7387-3230","authenticated-orcid":false,"given":"Herbert L.","family":"Bonkovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Monroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5750-1920","authenticated-orcid":false,"given":"Gayle","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Encarna","family":"Guill\u00e9n-Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8676-6864","authenticated-orcid":false,"given":"Maria Domenica","family":"Cappellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6108-367X","authenticated-orcid":false,"given":"Anna-Elisabeth","family":"Minder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8761-2784","authenticated-orcid":false,"given":"Ole","family":"Hother-Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1893-1914","authenticated-orcid":false,"given":"Paolo","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne T.","family":"Sweetser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Thapar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2023.06.013_bib1","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(09)61925-5","article-title":"Porphyrias","volume":"375","author":"Puy","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2023.06.013_bib2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/hep4.1297","article-title":"Acute hepatic porphyrias: review and recent progress","volume":"3","author":"Wang","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2023.06.013_bib3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.amjms.2021.03.004","article-title":"Biochemical diagnosis of acute hepatic porphyria: updated expert recommendations for primary care physicians","volume":"362","author":"Anderson","year":"2021","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jhep.2023.06.013_bib4","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/hep.29313","article-title":"Acute hepatic porphyrias: recommendations for evaluation and long-term management","volume":"66","author":"Balwani","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.06.013_bib5","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1056\/NEJMra1608634","article-title":"Porphyria","volume":"377","author":"Bissell","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2023.06.013_bib6","first-page":"17.20.11","article-title":"Porphyria diagnostics-part 1: a brief overview of the porphyrias","volume":"86","author":"Ramanujam","year":"2015","journal-title":"Curr Protoc Hum Genet"},{"key":"10.1016\/j.jhep.2023.06.013_bib7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ymgme.2019.03.002","article-title":"Pathogenesis and clinical features of the acute hepatic porphyrias (AHPs)","volume":"128","author":"Bonkovsky","year":"2019","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jhep.2023.06.013_bib8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ymgme.2019.07.002","article-title":"Acute hepatic porphyrias: current diagnosis & management","volume":"128","author":"Anderson","year":"2019","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jhep.2023.06.013_bib9","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/hep.30936","article-title":"EXPLORE: a prospective, multinational, natural history study of patients with\u00a0acute hepatic porphyria with recurrent attacks","volume":"71","author":"Gouya","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.06.013_bib10","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.amjmed.2014.06.036","article-title":"Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium","volume":"127","author":"Bonkovsky","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.jhep.2023.06.013_bib11","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40271-018-0319-3","article-title":"Patient perspective on acute intermittent porphyria with frequent attacks: a disease with intermittent and chronic manifestations","volume":"11","author":"Simon","year":"2018","journal-title":"Patient"},{"key":"10.1016\/j.jhep.2023.06.013_bib12","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7861\/clinmedicine.12-3-293","article-title":"Acute intermittent porphyria: fatal complications of treatment","volume":"12","author":"Stein","year":"2012","journal-title":"Clin Med (London)"},{"key":"10.1016\/j.jhep.2023.06.013_bib13","first-page":"104","article-title":"Quantifying the impact of symptomatic acute hepatic porphyria on well-being via patient-reported outcomes: results from the Porphyria Worldwide Patient Experience Research (POWER) study","volume":"64","author":"Dickey","year":"2023","journal-title":"JIMD Rep"},{"key":"10.1016\/j.jhep.2023.06.013_bib14","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13023-021-01742-3","article-title":"Health impact of acute intermittent porphyria in latent and non-recurrent attacks patients","volume":"16","author":"Buend\u00eda-Mart\u00ednez","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jhep.2023.06.013_bib15","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ymgme.2016.08.006","article-title":"Experiences and concerns of patients with recurrent attacks of acute hepatic porphyria: a qualitative study","volume":"119","author":"Naik","year":"2016","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jhep.2023.06.013_bib16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.21037\/tgh-2020-01","article-title":"The acute hepatic porphyrias","volume":"6","author":"Wang","year":"2021","journal-title":"Transl Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.06.013_bib17","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/bjh.14459","article-title":"Update review of the acute porphyrias","volume":"176","author":"Stein","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jhep.2023.06.013_bib18","series-title":"Alnylam announces approval of GIVLAARI\u00ae (givosiran) in Brazil for the treatment of acute hepatic porphyria (AHP) in adults [press release]","year":"2020"},{"key":"10.1016\/j.jhep.2023.06.013_bib19","series-title":"Givlaari, solution for injection (Givosiranum)","year":"2021"},{"key":"10.1016\/j.jhep.2023.06.013_bib20","series-title":"Givlaari Canada [product monograph]","year":"2020"},{"key":"10.1016\/j.jhep.2023.06.013_bib21","series-title":"Givlaari [package insert]","year":"2023"},{"key":"10.1016\/j.jhep.2023.06.013_bib22","series-title":"Givlaari, solution for injection (Givosiranum)","year":"2021"},{"key":"10.1016\/j.jhep.2023.06.013_bib23","series-title":"Obtained manufacturing and marketing approval for \u201cGiblari\u201d for the treatment of acute hepatic porphyria [press release]","year":"2021"},{"key":"10.1016\/j.jhep.2023.06.013_bib24","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2023.06.013_bib25","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1038\/mtna.2015.36","article-title":"Preclinical development of a subcutaneous ALAS1 RNAi therapeutic for treatment of hepatic porphyrias using circulating RNA quantification","volume":"4","author":"Chan","year":"2015","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jhep.2023.06.013_bib26","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa1807838","article-title":"Phase 1 trial of an RNA interference therapy for acute intermittent porphyria","volume":"380","author":"Sardh","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2023.06.013_bib27","series-title":"Presented at: international congress on porphyrins and porphyrias","article-title":"A drug-drug interaction study to investigate the effect of givosiran on the activity of 5 major drug metabolizing CYP450 enzymes in subjects with acute intermittent porphyria (AIP) who are chronic high excreters (CHE)","author":"Vassiliou","year":"2019"},{"key":"10.1016\/j.jhep.2023.06.013_bib28","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/liv.15090","article-title":"Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study","volume":"42","author":"Ventura","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2023.06.013_bib29","series-title":"WMA declaration of Helsinki - ethical principles for medical research involving human subjects","year":"2013"},{"key":"10.1016\/j.jhep.2023.06.013_bib30","series-title":"ICH harmonised tripartite guideline: guideline for good clinical practice E6(R1)","year":"1996"},{"key":"10.1016\/j.jhep.2023.06.013_bib31","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","article-title":"A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity","volume":"34","author":"Ware","year":"1996","journal-title":"Med Care"},{"key":"10.1016\/j.jhep.2023.06.013_bib32","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jhep.2023.06.013_bib33","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/17474124.2022.2110469","article-title":"Hyperhomocysteinemia in acute hepatic porphyria (AHP) and implications for treatment with givosiran","volume":"16","author":"Ventura","year":"2022","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.06.013_bib34","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s13023-022-02463-x","article-title":"Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study","volume":"17","author":"Wang","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jhep.2023.06.013_bib35","series-title":"Panhematin [package insert]","year":"2017"},{"key":"10.1016\/j.jhep.2023.06.013_bib36","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1002\/cncr.29415","article-title":"How much do cancer-related symptoms contribute to health-related quality of life in lung and colorectal cancer patients? A report from the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium","volume":"121","author":"Kenzik","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2023.06.013_bib37","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/hrt.2003.013995","article-title":"Comparison of the Short Form (SF)-12 health status instrument with the SF-36 in patients with coronary heart disease","volume":"90","author":"M\u00fcller-Nordhorn","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.jhep.2023.06.013_bib38","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s00167-013-2776-5","article-title":"The minimal clinically important\u00a0difference in the Oxford knee score and Short Form 12 score after\u00a0total knee arthroplasty","volume":"22","author":"Clement","year":"2014","journal-title":"Knee Surg Sports Traumatol Arthrosc"},{"key":"10.1016\/j.jhep.2023.06.013_bib39","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3171\/2012.1.SPINE11842","article-title":"Minimum clinically important difference in pain, disability, and quality of life after neural decompression and fusion for same-level recurrent lumbar stenosis: understanding clinical versus statistical significance","volume":"16","author":"Parker","year":"2012","journal-title":"J Neurosurg Spine"},{"key":"10.1016\/j.jhep.2023.06.013_bib40","series-title":"Self-reported population health: an international perspective based on EQ-5D","year":"2014"},{"key":"10.1016\/j.jhep.2023.06.013_bib41","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4187\/respcare.03272","article-title":"Estimation of minimal clinically important difference in EQ-5D visual analog scale score after pulmonary rehabilitation in subjects with COPD","volume":"60","author":"Zanini","year":"2015","journal-title":"Respir Care"},{"key":"10.1016\/j.jhep.2023.06.013_bib42","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual Life Outcomes"},{"issue":"suppl 1","key":"10.1016\/j.jhep.2023.06.013_bib43","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/S0168-8278(20)30664-4","article-title":"Twelve-month interim analysis of efficacy and safety of givosiran, an investigational RNAi therapeutic for acute hepatic porphyria, in the ENVISION open label extension [abstract AS085]","volume":"73","author":"Sardh","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.06.013_bib44","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejim.2020.04.002","article-title":"Hyperhomocysteinemia in patients with acute porphyrias: a potentially dangerous metabolic crossroad?","volume":"79","author":"Ventura","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jhep.2023.06.013_bib45","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejim.2021.06.023","article-title":"Hyperhomocysteinemia in patients with acute porphyrias: a possible effect of ALAS1 modulation by siRNAm therapy and its control by vitamin supplementation","volume":"92","author":"Ricci","year":"2021","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jhep.2023.06.013_bib46","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/joim.13341","article-title":"Homocysteine elevation in givosiran treatment: suggested ALAS1 siRNA effect on cystathionine beta-synthase","volume":"290","author":"Vassiliou","year":"2021","journal-title":"J Intern Med"},{"key":"10.1016\/j.jhep.2023.06.013_bib47","first-page":"85","article-title":"Normal reference ranges for urinary \u03b4-aminolevulinic acid and porphobilinogen levels","volume":"57","author":"Agarwal","year":"2021","journal-title":"JIMD Rep"},{"key":"10.1016\/j.jhep.2023.06.013_bib48","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1136\/thoraxjnl-2015-207782","article-title":"The EQ-5D-5L health status questionnaire in COPD: validity, responsiveness and minimum important difference","volume":"71","author":"Nolan","year":"2016","journal-title":"Thorax"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823049334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823049334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:49:52Z","timestamp":1759175392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827823049334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0168827823049334"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2023.06.013","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2023.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}